Aetion

Webinar: How leading-edge R&D teams are using RWE. Register here.

Aeiotn COVID icon (1)

COVID-19 conversation and collaboration

Aetion is committed to advancing COVID-19 research through our work with industry, including FDA, biopharma, and working groups such as the COVID-19 Evidence Accelerator. This page features a snapshot of our and our collaborators’ latest thinking on how real-world data can inform understanding of and response to coronavirus disease.

Usage of medications in-hospital

This chart—generated in Real-Time Insights and Evidence, a solution powered by Aetion and HealthVerity—shows U.S. hospital visits over time, with corresponding use of common medicines used to treat COVID-19.

https://aetion.com/wp-content/uploads/2021/02/Screen-Shot-2021-02-23-at-11.35.46-AM-e1614098233661.png

Latest news

March 4, 2021

How RWE can support drug development during COVID-19 and beyond: Q&A with Dr. Diana Brainard of Gilead Sciences
February 25, 2021

How RWE can advance understanding of—and boost public confidence in—COVID-19 vaccine safety
February 24, 2021

Coronavirus infection leads to immunity that’s comparable to a COVID-19 vaccine

Los Angeles Times

February 24, 2021

COVID-19 antibodies may protect against reinfection later, study suggests

CNN

January 21, 2021

Real-world data in the era of COVID-19: Expert perspectives on the changing data landscape
January 7, 2021

Research spotlight: Using RWE to evaluate complications of COVID-19
See more news

Real-Time Insights & Evidence

A COVID-ready solution powered by Aetion and HealthVerity

Learn more

The Evidence Digest

Subscribe to our newsletter for insights and updates on research and applications for real-world evidence in life sciences and value-based health care.

arrowcalendarchevronclosecollapsecountdownfacebookflickrinstagramlinelinkedinlocationpinsearchsocialtwitteryoutube